Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Epistemonikos ID: 34f767c0327831cdd04dacd5d306d8b119f4ca9c
First added on: Jul 03, 2025